SCHEMBL5760211

SCHEMBL5760211

N#Cc1cccc(N2CCN(C(=O)c3c(-c4ccccc4)ccn3CC(=O)O)CC2)c1

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SMO Q99835 1/20 0.43
CHRM4 P08173 2/20 0.43
FNTA P49354 1/20 0.43
FNTB P49356 1/20 0.43
POLB P06746 2/20 0.42
NOTUM Q6P988 1/20 0.42
SLC6A7 Q99884 2/20 0.42
DRD2 P14416 3/20 0.42
DRD3 P35462 2/20 0.41
USP2 O75604 1/20 0.40
LMNA P02545 1/20 0.40
MAPT P10636 1/20 0.40
TSHR P16473 1/20 0.40
MAPK1 P28482 1/20 0.40
NAMPT P43490 1/20 0.40
ADAMTS5 Q9UNA0 1/20 0.40
MEN1 O00255 1/20 0.40
KMT2A Q03164 1/20 0.40
SLC6A9 P48067 1/20 0.40
ESR1 P03372 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6494330 0.84 USP2 (0.47) POLBSLC6A7DRD2DRD3USP2
SCHEMBL6494963 0.78 DRD2 (0.43) SMOCHRM4FNTAFNTBNOTUM
SCHEMBL1382166 0.76 DRD2 (0.48) SMOCHRM4POLBNOTUMSLC6A7
SCHEMBL1383360 0.76 NOTUM (0.46) SMOCHRM4POLBNOTUMSLC6A7
SCHEMBL5760301 0.76 SMO (0.48) SMOCHRM4POLBNOTUMSLC6A7
SCHEMBL6502353 0.74 NOTUM (0.44) SMOCHRM4NOTUMSLC6A7DRD2
SCHEMBL5751095 0.74 SMO (0.47) SMOCHRM4NOTUMSLC6A7MEN1
SCHEMBL5763718 0.73 DRD2 (0.60) CHRM4NOTUMDRD2DRD3USP2
SCHEMBL1382820 0.72 SMO (0.49) SMOCHRM4POLBNOTUMSLC6A7
SCHEMBL1380695 0.72 SLC6A9 (0.45) SMOCHRM4NOTUMSLC6A7DRD2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1641765-A1 ARYL-HETEROAROMATIC PRODUCTS, COMPOSITIONS CONTAINING SAME AND USE THEREOF Aventis Pharma S.A. (FR) 2006-04-05 EP disclosed
US-20050014765-A1 Aryl-heteroaromatic products, compositions comprising them and use AVENTIS PHARMA S.A. (FR) 2005-01-20 US disclosed
WO-2004108685-A1 ARYL-HETEROAROMATIC PRODUCTS, COMPOSITIONS CONTAINING SAME AND USE THEREOF AVENTIS PHARMA S.A. (FR) 2004-12-16 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050014765-A1 Aryl-heteroaromatic products, compositions comprising them and use AHR, ARNT, MYC SMO 2088/4885CHRM4 4347/4885FNTA 1250/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.